Protecting against ischemia-reperfusion injury: Antiplatelet drugs, statins, and their potential interactions

Keyphrases

• Statins 100%
• Ischemia-reperfusion Injury 100%
• Potential Interaction 100%
• Antiplatelet Drugs 100%
• Dipyridamole 50%
• Simvastatin 50%
• Infarct Size 50%
• Inducible Nitric Oxide Synthase 33%
• Cyclooxygenase-2 33%
• Phosphoinositide 3-kinase (PI3K) 33%
• Protective Effect 33%
• Aspirin 33%
• Endothelial Nitric Oxide Synthase (eNOS) 33%
• Myocardial Infarct Size 33%
• Liming Effect 33%
• Nitric Oxide Synthase 2 33%
• Low-dose Aspirin 33%
• Ischemia 16%
• Therapeutic Agents 16%
• High Dose 16%
• Adenosine 16%
• Adenosine Receptors 16%
• Downstream Effectors 16%
• Acute Myocardial Infarction 16%
• Uptake Inhibitor 16%
• Antiplatelet Agents 16%
• Cilostazol 16%
• Ectonucleotidases 16%
• Phosphodiesterase 3 Inhibitor 16%
• Antiplatelet 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 100%
• Reperfusion Injury 100%
• Antithrombocytic Agent 100%
• Acetylsalicylic Acid 66%
• Inducible Nitric Oxide Synthase 66%
• Infarction 50%
• Simvastatin 50%
• Dipyridamole 50%
• Cyclooxygenase 2 33%
• Heart Infarction 33%
• Phosphatidylinositol 3 Kinase 33%
• Endothelial Nitric Oxide Synthase 33%
• Ischemia 16%
• Adenosine 16%
• Adenosine Receptor 16%
• Acute Heart Infarction 16%
• Reuptake Inhibitor 16%
• Cilostazol 16%
• 5' Nucleotidase 16%
• Phosphodiesterase III Inhibitor 16%
• Antiplatelet 16%